RT Journal Article
SR Electronic
T1 REG endpoint validation: Do database asthma control measures predict future risk?
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P3022
VO 44
IS Suppl 58
A1 Guy Brusselle
A1 Richard J. Martin
A1 Annie Burden
A1 Alexandra Dima
A1 Emilio Pizzichini
A1 Janet Holbrook
A1 Nikolaos G. Papadopoulos
A1 Todor Popov
A1 Gene Colice
A1 Helen K. Reddel
A1 Julie von Ziegenweidt
A1 Alison Chisholm
A1 David Price
YR 2014
UL http://erj.ersjournals.com/content/44/Suppl_58/P3022.abstract
AB Aim: Improved understanding of patient characteristics associated with exacerbations (EXBs) may provide opportunity to minimize future risk. We assessed whether database asthma control can predict future EXBs.Methods: Used a research database to select clinical records of patients aged 18–60yrs with an asthma diagnosis, continuous records over 1 baseline & 1 outcome yr and no other chronic respiratory disease or maintenance oral steroids. Two baseline control measures were evaluated: risk domain asthma control (RDAC) & overall control (OAC). RDAC was absence of: exacerbations, unplanned asthma-related out patient appointments, and antibiotics with evidence of respiratory review (ABX). OAC was: RDAC+average salbutamol ≤200µg/day. RDAC/OAC components predictive of outcome EXBs in univariable models were entered into a multivariable model and stepwise reduced. EXBs were: oral steroid courses with evidence of respiratory review (OS), asthma-related hospital admission or emergency room [ER] attendance.Results: Of 1558 patients (60% female), 73% and 42% satisfied criteria for RDAC and OAC control, respectively, at baseline.View this table:Baseline Predictors of EXB riskConclusions: Classification as RDAC or OAC at baseline predicted lower EXB rates in the following year. OS, ABX and asthma-related ER attendance independently predicted increased EXB risk regardless of “current control” as indicated by salbutamol use.